AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Hart, L. A. [1 ]
Carlson, J. J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN135
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [41] Everolimus for the treatment of advanced renal cell carcinoma
    Amato, Robert
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) : 1143 - 1155
  • [42] Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
    Tannir, Nizar M.
    Pal, Sumanta K.
    Atkins, Michael B.
    ONCOLOGIST, 2018, 23 (05): : 540 - 555
  • [43] Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
    Kaur, G.
    Rai, P.
    Singh, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1476 - S1476
  • [44] ECONOMIC EVALUATION OF EVEROLIMUS VERSUS SORAFENIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA AFTER FAILURE ON TREATMENT WITH SUNITINIB
    Casciano, R.
    Chulikavit, M.
    Di Lorenzo, G.
    Stern, L.
    Liu, Z.
    Wang, X.
    Garay, C.
    Garrison, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 295 - 296
  • [45] Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
    Chen, Pingyu
    Fu, Chang
    Shen, Lin
    Fei, Zhengyang
    Luo, Mengjie
    Chen, Yanqiu
    Li, Hongchao
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [46] SECOND-LINE TREATMENT WITH SORAFENIB IN POOR-RISK ADVANCED RENAL CELL CARCINOMA: A CASE REPORT
    Gasparro, Donatello
    Tarasconi, Sara
    ANTICANCER RESEARCH, 2012, 32 (05) : 1950 - 1951
  • [47] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [48] Second-line treatment for renal cell cancer
    G Di Lorenzo
    S De Placido
    C Buonerba
    British Journal of Cancer, 2012, 106 : 617 - 618
  • [49] Second-line treatment for renal cell cancer
    Di Lorenzo, G.
    De Placido, S.
    Buonerba, C.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 617 - 618
  • [50] Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
    Schmidinger, M.
    Motzer, R. J.
    Powles, T.
    Escudier, B.
    Tannir, N. M.
    Mainwaring, P. N.
    Rini, B. I.
    Hammers, H. J.
    Donscov, F.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D. Y. C.
    Aftab, D. T.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Pal, S.
    Hutson, T. E.
    Choueiri, T. K.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S187 - S188
12345